A therosclerosis is a multifactorial chronic disease characterized by lipid deposition, inflammatory response, and abnormal remodeling of the intima of large and mediumsized arteries. [1] [2] [3] [4] [5] Among the various mechanisms involved in atherogenesis, LDLs (low-density lipoproteins) retention and oxidation generate a local inflammatory response including endothelial activation, monocyte recruitment, and cholesterol accumulation in macrophages. 1, [3] [4] [5] Activated endothelial cells express adhesion molecules, ICAM-1 (intercellular adhesion molecule-1), and VCAM-1 (vascular cell adhesion molecule-1), IL (interleukins), and chemokines such as MCP-1 (monocyte chemoattractant protein-1) that promote the recruitment of mononuclear cells, their migration in the intima and their differentiation into macrophages. [1] [2] [3] [4] In the intima, oxLDLs (oxidized LDLs) and other modified LDLs are taken up by macrophages which accumulate cholesterol, thereby forming foam cells and fatty streaks, a feature of early atherosclerotic lesions. [1] [2] [3] [4] Activated endothelial cells and leukocytes in the intima may oxidize LDLs and produce proinflammatory cytokines, such as IL-1β, IL-6, or TNF-α (tumor necrosis factor-α), that participate in the local inflammatory response. 1 These inflammatory factors activate various cellular signaling pathways, among them the sphingolipid pathway that generates bioactive lipid messengers involved in the regulation of cell adhesion, migration, proliferation, survival, and death. 6 Sphingolipid mediators such as ceramide and derivatives can be generated by de novo synthesis or by the degradation of sphingomyelin or other complex sphingolipids. 6 In cultured vascular cells, oxLDLs and inflammatory cytokines trigger the activation of SMases (sphingomyelinases) and the generation of Studies based on genetically engineered cells, pharmacological inhibitors, and cell-permeant ceramides suggest that sphingolipid mediators may contribute to atherogenesis. [7] [8] [9] A recent study on human carotid plaques showed that high sphingolipid levels are associated with plaque inflammation and instability. 10 The de novo sphingomyelin synthesis is involved in the regulation of lipoprotein metabolism 11 and in atherogenesis, as shown by reduced atherosclerosis in macrophagic sphingomyelin synthase 2-deficient LDLR −/− mice, 12 and in Apoe −/− mice treated by myriocin, a serine palmitoyltransferase inhibitor that decreases the biosynthesis of sphingosine, ceramide, and sphingomyelin. 13 The role of SMases has been reported in atherogenesis. 7, 8 The secretory aSMase (acid SMase), which is upregulated by inflammatory cytokines, could be implicated in lipoprotein retention, foam cell formation, and, conversely, its deficiency is associated with reduced atherogenesis in aSMase −/− / Apoe −/− and aSMase −/− /LDLR −/− mice. 14, 15 This could be in part because of the lowering of cholesterol or the reduction of inflammation. However, unexpectedly, AAV (adenoassociated viral)-mediated expression of secretory aSMase reduces atherosclerosis in Apoe −/− mice. 16 A nSMase (neutral sphingomyelinase), more specifically the nSMase2 (type 2-neutral sphingomyelinase), is activated in vascular cells by stress agents such as oxLDLs, 17 TNF-α, 18, 19 IL-1β, 20 interferon γ, 21 shear stress, 22 and oxidative stress, 23 and may contribute to endothelium activation, 24, 25 phagocyte chemotaxis 26 and inflammation. 27 This inflammatory response may play an atherogenic role but, reversely, the defect of nSMase2 induces an accumulation of cholesterol in fibroblasts, thus may also be proatherogenic. 28 As the role of nSMase2 in atherosclerosis is still debated, this study was performed to clarify its involvement in atherogenesis. For this purpose, we used a genetic double mutant mouse model deficient in both nSMase2 activity and Apoe −/− expression. The genetic deficiency of nSMase2 (encoded by the Smpd3, sphingomyelin phosphodiesterase 3 gene) is observed in mice homozygous for the Fro (fragilitas ossium) mutation of the Smpd3 gene (Smpd3 fro/fro ) 29 and in Smpd3-KO mice. 30 The Fro mutation of the smpd3 gene induces the loss of the C-terminal domain containing the active site of nSMase2 so that Fro mice bearing the homozygous fro/ fro mutation are deficient in nSMase2 activity. Alternatively, we used a pharmacological model of long-term inhibition of nSMase2 by GW4869 in Apoe −/− mice. 31 In the 2 experimental models, nSMase2 deficiency or inhibition significantly reduced the size of atherosclerotic lesions and lipid deposition, via, in part, a Nrf2-dependent antiinflammatory mechanism.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Antibodies and Reagents
A full list of all reagents and antibodies used are listed in the expanded Methods in the online-only Data Supplement.
Animals
Animal protocol was approved by the Committee on Research Animal Care of INSERM UMR1048 Center (protocol APAFIS number 3802-2016012614366248v5). Double mutant Apoe −/− and nSMase2-deficient mice were obtained as described in the expanded Methods in the online-only Data Supplement. Male C57BL/6 WT and C57BL/6 Nrf2 −/− transgenic 6 to 12-week-old mice were used as described previously. 32, 33 Animal experiment was conducted in agreement with the recommendation on design and execution of animal atherosclerosis studies.
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Plaque Formation Analysis
The extent of atherosclerosis development and plaque inflammation were analyzed as described in the expanded Methods in the onlineonly Data Supplement.
LDL Isolation and Oxidation
LDL from human pooled sera were prepared by ultracentrifugation. 17 The extent of LDL oxidation was monitored by measuring the thiobarbituric acid-reactive substance content.
17
Genes Expression
Gene expression was analyzed as described in the expanded Methods in the online-only Data Supplement.
nSMase and Lipids Determinations
nSMase activity was determined as reported. 17 Additionally, lipid analysis were performed on lipids samples obtained after Bligh and Dyer extraction. 35 Expanded Methods in the online-only Data Supplement.
Western Blot Analysis
Protein expressions were quantified by Western blot analysis on cell extracts or after nuclear or cytosol extractions as described in the expanded Methods in the online-only Data Supplement.
Cytokine and Nitrite Quantification
IL-6, IL-10, MCP-1, and TNF-α were quantified in the culture media using a BD cytometric bead array (CBA 552364), and IL-1β was quantified using the Mouse IL-1β Elisa Ready-set-GO (ref eBioscience: 887013-22). Nitrite quantification was performed by the Griess method (Molecular probes D1692).
Monocyte Adhesion and Migration Assays
Migration was studied in Boyden chamber using membrane 8 Figure 1A) . The en face analysis of aortas stained with oil Altogether, these data show that the genetic deficiency of nSMase2 or its pharmacological inhibition by GW4869 significantly reduced the size of atherosclerotic areas and the accumulation of macrophages in the lesions of Apoe −/− mice. To investigate the mechanism of this atheroprotective effect, we evaluated the effect of nSMase2 deficiency on several metabolic and inflammatory atherogenic factors in the Apoe −/− murine model. As expected, the deficiency or inhibition of nSMase2 activity resulted in a significant decrease in plasma ceramide levels, particularly in 24:1, 22:0, and 24:0 ceramide levels, as previously reported by Qin et al. 28 Plasmatic SM and phospholipid levels were not affected by nSMase2 deficiency or inhibition ( Figure III in the online-only Data Supplement).
Interestingly, nSMase2 deficiency or pharmacological inhibition by GW4869 induced no significant variation of plasma cholesterol, HDL (high-density lipoprotein), LDL, triglycerides nor free fatty acids (Table) . These data indicate that the atheroprotective mechanism of nSMase2 mutation/inhibition does not result from plasma cholesterol changes.
Note that no weight variations were observed after GW4869 treatment ( Figure IV in the online-only Data Supplement).
Inhibition of nSMase2 Reduces Endothelial Cell Activation and Monocyte Adhesion
In agreement with previous reports, 39 oxLDLs induced an increase of ceramide in CRL2181 which resulted from nSMase activation, as it was inhibited by GW4869 ( Figure V in the online-only Data Supplement).
As the adhesion of mononuclear cells to the activated endothelium plays a major role in early atherogenesis, [1] [2] [3] [4] and as nSMase2 was implicated in VCAM-1 expression, 40 we investigated whether nSMase2 inhibition altered the expression of VCAM-1 in CRL2181 and the adhesion of murine macrophages. OxLDLs stimulated nSMase activity in CRL2181 and this is inhibited by nSMase2 siRNA treatment (Figure VIA in the online-only Data Supplement). OxLDLs also induced ICAM-1 and VCAM-1 mRNAs and the adhesion of fluorescent calcein-stained RAW264.7 to CRL2181 (Figure 2A through 2C ). All these events were inhibited when endothelial cells were treated with the nSMase inhibitor GW4869 or were silenced for nSMase2 using a smpd3 si-RNA (Figure 2) .
In Boyden Chamber assays, the migration of RAW264.7 monocytes was stimulated by the culture medium of CRL2181 treated by oxLDLs, and this was inhibited by GW4869 ( Figure  VI Altogether these results suggest that nSMase2 inhibition reduces endothelium activation, and the subsequent monocyte recruitment, adhesion, and migration. 
Activation of Nrf2 in Response to nSMase2 Inhibition in Endothelial Cells
As the redox-sensitive Nrf2 transcription factor could be downregulated by ceramide 41 which may also stimulate the expression of VCAM-1 and adhesion of monocytes to activated endothelium, 42 we checked whether Nrf2 could play a role in the anti-inflammatory response resulting from nSMase2 inhibition. CRL2181 were grown on 6-multiwell culture plates and stimulated for 4 h by oxLDLs (oxidized low-density lipoproteins; 100 μg/mL) after 30 min preincubation with GW4869 (10 μmol\L, A, B) . Alternatively, cells were treated with scramble (Scr) or nSMase2 siRNAs (siSmpd3, A, C). RAW264.7 macrophages stained by calcein were added to activated CRL2181 (50 000 cells/well) for 30 min. Adhesion was quantified by measuring the fluorescence of cell lysates (B, C). The results are normalized to the nonstimulated control (A) or oxLDL treated by Scr siRNA (C). D, G, Quantification of VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) mRNAs by RT-qPCR in comparison with GAPDH. The data are expressed as mean±SEM of at least 3 independent experiments. Statistical analysis was performed using t test with Dunnett correction when >2 groups were compared (* means compared with untreated control and # means compared with oxLDL treated cells). *,#P<0.05, **,##P<0.01, ***P<0.001. July 2018 . Implication of Nrf2 (nuclear factor [erythroid-derived 2]-like 2 or NF-E2-related factor-2) in the inhibitory effect of GW4869 on CRL2181 activation. A, Time-course of Nrf2 nuclear translocation evoked by GW4869 (10 µmol\L) in CRL2181. B, VCAM-1 (vascular cell adhesion molecule-1) mRNAs expression in CRL2181 stimulated by oxLDLs (oxidized low-density lipoproteins; 100 μg/mL) for 4 h±DEM (100 µmol\L) or trigonelline (TRG; 10 µmol\L), quantified by RT-qPCR in comparison with GAPDH. C, Monocyte adhesion to endothelial cells activated as described in B. D, Expression of Nrf2 mRNA in CRL2181 incubated for 48 h with Nrf2 siRNA. E, F, Effect of Nrf2 siRNA on the expression of ICAM-1 (intercellular adhesion molecule-1; E) and VCAM-1 (F) mRNAs induced by oxLDL. G, H, Effect of Nrf2 siRNAs on the adhesion of calcein-stained RAW 264.7 macrophages on CRL2181 activated for 4 h by oxLDL (100 μg/mL). The data (3 separate experiments) were expressed as mean±SEM. In A, statistical analysis was performed using ANOVA test (Dunnett correction) and (B-H) statistical analysis was performed using t test and Dunnett correction when >2 conditions were tested. *,$ or #P<0.05; **P<0.01. $: compared with untreated cells, *: compared with oxLDLs or oxLDLs+scr-treated cells, #: compared with oxLDL+GW4869-treated cells.
We then checked the effect of Nrf2 translocation on endothelium inflammation. We first used a pharmacological approach as reported by Kobayashi et al 43 : DEM (diethylmaleate), a potent activator of Nrf2, inhibited the expression of VCAM-1 and the adhesion of RAW264.7 cells to CRL2181 ( Figure 3B and 3C) , thus indicating that Nrf2 induction mimicked the protective effect of GW4869. In contrast, TRG (trigonelline), a pharmacological inhibitor of Nrf2 activation, prevented the inhibitory effect of GW4869 on monocyte adhesion to CRL2181 (Figure 3B and 3C). Note that DEM and trigonelline did not block nSMase activation induced by oxLDLs ( Figure VIII in the online-only Data Supplement). Alternatively, Nrf2 silencing by siRNAs, under conditions leading to 50% decrease of Nrf2 expression in CRL2181, reversed by 50% the protective effect of GW4869 on ICAM-1 and VCAM-1 mRNA expression, and on the adhesion of RAW264.7 ( Figure 3D through 3H).
Altogether these results suggest that nSMase inhibition prevents the endothelial inflammation through a Nrf2-dependent mechanism.
nSMase2 Inhibition Reduces the Inflammatory Response of Macrophagic Cells
In atherosclerotic lesions, macrophages release pro-and anti-inflammatory cytokines, depending on their polarization, M1 being proinflammatory, and M2 considered as repair and anti-inflammatory. 44 Previous reports suggested that the inflammatory response evoked by lipopolysaccharides (LPS) could involve nSMase2. [45] [46] [47] We investigated whether nSMase2 inhibition may directly affect the inflammatory phenotype of macrophages, that is, the production of cytokines, using either LPS-stimulated peritoneal macrophages isolated from Apoe Figure 5C and 5D) . Altogether, these data indicated that nSMase2 inhibition decreases vascular inflammation by reducing the recruitment of monocytes to endothelium and macrophage M1 differentiation.
Nrf2 Participates to the Reduced Inflammatory Response of Macrophages After nSMase2 Inhibition
As nSMase2 inhibition significantly reduced endothelial cell activation via a Nrf2-dependent mechanism, we hypothesized that Nrf2 could be also involved in the reduced inflammatory response of macrophages. In vitro experiments performed on RAW264.7 showed that cells treated by GW4869 alone exhibited a rapid nuclear translocation of Nrf2 (Figure 6A and 6B; Figure VIID through VIIF in the online-only Data Supplement). Confocal microscopy experiments showed that Nrf2 accumulated in the nucleus after 2 hours of GW4869 treatment ( Figure 6A ). In vivo, the total Nrf2 expression was modestly increased in the aorta of animals injected with GW4869 ( Figure XVA in the online-only Data Supplement).
The anti-inflammatory mechanism, because of Nrf2 activation was then investigated. The nuclear translocation of Nrf2 triggers the expression of cytoprotective genes and their protein products, among them HO-1 (heme oxygenase 1) which exerts strong antioxidant and anti-inflammatory functions. 48 To confirm the activation of Nrf2 in our model, we checked whether nSMase2 inhibition stimulated the expression of HO-1 in vitro and in vivo. As shown in Figure 7A , GW4869 significantly increased the expression of HO-1 in RAW264.7, in a time-dependent manner. Moreover, the decrease in HO-1 expression resulting from long-term LPS treatment (24 hours) was reversed by GW4869 ( Figure 7B ). In vivo, the expression of HO-1 was highly increased in aortic sinus of Apoe All these data suggest that the Nrf2/HO-1 axis is activated and may be involved in the anti-inflammatory response after pharmacological or genetic nSMase2 inhibition. A recent report from Kobayashi et al 43 indicated that Nrf2 could directly act as an anti-inflammatory factor leading to the early inhibition of IL-1β and IL-6 expression. To test this hypothesis, cells were incubated from 0 to 6 hours with LPS and GW4869: at this incubation time, LPS induced an early expression and secretion of IL-1β which was in part reversed by GW4869 ( Figure 7C and 7D). These events (protective effect of GW4869 on IL-1β expression and secretion) are probably not due to the increased expression of HO1, as they occurred much earlier during the stimulation of macrophages by LPS. Altogether these data indicated that Nrf2 exerts an anti-inflammatory effect only partly dependent on HO-1 expression.
To confirm the role of Nrf2 in the decreased inflammation resulting from nSMase inhibition, 2 experimental approaches were tested: First, LPS-induced inflammation in macrophages was monitored by measuring IL-1β and IL-6 mRNA expression, using the pharmacological inhibitor/activator strategy. We observed that DEM, the Nrf2 activator, mimicked the protective effect of GW4869 on IL-1β and IL-6 mRNA expression in agreement with previous reports, 43 whereas the Nrf2 inhibitor trigonelline, reduced its protective effect ( Figure 7E and 7F) . Second, the effect of GW4869 was evaluated on peritoneal macrophages from Nrf2-KO mice stimulated by LPS. As shown in Figure 7G and 7H, Figure 6 . nSMase (neutral sphingomyelinase) inhibition induces Nrf2 (nuclear factor [erythroid-derived 2]-like 2 or NF-E2-related factor-2) nuclear translocation. A, Confocal microscopy of RAW264.7 stimulated or not with GW4869 (2 h). B, Cells were stimulated by GW4869 at various times and Nrf2 nuclear translocation was quantified by Western blot as described in the Materials and Methods section. The data are expressed as mean±SEM. Statistical analysis was performed using ANOVA test followed by Dunnett post hoc test. Representative of at least 3 independent experiments. *P<0.05.
GW4869 was unable to prevent the expression of IL-1β and IL-6 mRNAs evoked by LPS in Nrf2-KO macrophages. Altogether these results demonstrate that Nrf2 is involved in the anti-inflammatory response evoked by nSMase2 inhibition in macrophages.
Discussion
Clinical evidence and studies on animal models show that inflammation is present at each step of atherosclerosis development.
1,3-5 The mechanisms leading to the inflammatory response in the vascular wall are only partly identified. This study reports that inflammation and atherosclerosis lesions are strongly decreased in response to nSMase2 inhibition, elicited either pharmacologically when using the nSMase inhibitor GW4869, 31 or in genetically nSMase2-deficient Apoe
fro/fro mice. GW4869 is the most widely used nSMase2 inhibitor. GW4869 has been used in many studies to demonstrate the implication of nSMase2 in response to TNF-α, 49 HLA, 50 oxLDLs, 17 in the secretion of hyaluronic acid, 28 or miRNAs. 51 Recently, Airola et al 52 confirmed that GW4869 acts as a phosphatidylserine-competitive inhibitor of nSMase2, with an IC 50 around 1 μmol\L.
An important point is that the pharmacological or genetic inhibition of nSMase2 was not associated with plasma lipoprotein changes, SM accumulation nor cholesterol level modification in our mice models, in agreement with Stoffel group who reported that nSMase2 invalidation did not generate any accumulation of SM, cholesterol, phosphatidylethanolamine, and phosphatidylcholine. 30 These data suggest that the antiatherogenic effect resulting from nSMase2 inhibition is attributable to a direct effect on the arterial wall.
The lower inflammation patterns observed in the vascular wall of Apoe +/+ mice with GW4869, emphasize the role of nSMase2 and ceramide in inflammation and atherosclerosis development. nSMase2 hydrolyses an SM pool located in the inner leaflet of the plasma membrane, which generates ceramide 40 in all cell types, including vascular cells and macrophages. 7 Ceramide is thought to play a proinflammatory role within the plaque, as supported by studies showing its colocalization with CD68, MCP-1, or IL-6 in human atherosclerotic lesions. 10 In RAW264.7, ceramide may induce IFN-γ and iNOS expression, and Stat1 phosphorylation via the activation of PP1 (protein phosphatase 1) and PP2A (protein phosphatase 2A) 53 which are necessary for IFN-γ-synergized with LPS to induce iNOS/NO biosynthesis. 54 Likewise, our data indicate that iNOS mRNA expression and Stat1 phosphorylation elicited by LPS are decreased by GW4869. Several proatherogenic/inflammatory agents, including TNF-α, oxLDLs, IL-1β, or endothelin-1, may activate nSMase2 and ceramide production. [17] [18] [19] [20] [21] [23] [24] [25] [26] [27] For instance, in hepatocytes, IL-1β activates nSMase2 via a signaling pathway implicating IL1-R1 (IL1-receptor1), JNK (c-Jun N-terminal kinase), IRAK-1 (interleukin-1 receptoractivated protein kinase), and PP2A. 55 In neuronal cells, IL-1β activates nSMase2 which leads to IL-6 secretion via src. 56, 57 In HL-60, INFγ, and TNF-α activate nSMase, which stimulates their differentiation into monocytes. 21 Conversely, little is known concerning the implication of nSMase2 in the expression of cytokines and inflammatory factors. Here, we show that nSMase2 inhibition decreased the expression of inflammatory cytokines evoked by LPS in macrophages, and the activation of endothelial cell induced by oxLDLs, together with a decrease of ceramide level in the blood, in macrophages, endothelial cells, and in vascular tissues of animal models. These data suggest that nSMase2 and ceramide may directly modulate inflammation, possibly via an autoamplification loop in which they stimulate the expression of inflammatory cytokines, which in turn activate the sphingolipid pathway to maintain inflammation. Conversely, the inhibition of nSMase2 may inhibit inflammation at 2 levels, via a short-time mechanism implicating Nrf2, and long-term action, by decreasing the production of proinflammatory ceramide.
Our data indicate that nSMase2 inhibition leads to Nrf2 activation, which suggests that nSMase2 negatively regulates Nrf2 signaling. The anti-inflammatory function of Nrf2 has been largely reported, in macrophages 43, 58 or in endothelial cells in which the Nrf2/HO-1 axis could inhibit NF-κB activation and the expression of inflammatory genes (VCAM-1, ICAM-1, and MCP-1). 59 Under unstressed conditions, Nrf2 is maintained inactive in the cytosol by its repressor, Keap1. Once activated in response to injury and inflammation stimuli, Nrf2 translocates into the nucleus, binds to the antioxidant response element-controlled genes, thereby generating antioxidant and cytoprotective signaling pathways. Our data show that GW4869 stimulates a sustained nuclear translocation and activation of Nrf2 in both endothelial cells and macrophages. OxLDLs and LPS are known Nrf2 inducers, so one hypothesis is that Nrf2 activation by these agents, could be increased or more sustained when ceramide generation is lower or inhibited. This is in agreement with Park et al, 41 who reported that the nuclear translocation and activation of Nrf2, and the expression of its target genes such as glutathione S-transferases, are inhibited by ceramide. A balance between ceramide and Nrf2 is also observed during reperfusion, after coronary artery occlusion and myocardial ischemia, as shown by Reforgiato's 60 group who reported that injury (associated to an increase of inflammation) was reduced by myriocin treatment. These authors established a link between the ceramide decrease and the expression of the Nrf2 target HO-1. 60 Interestingly, our different approaches such as mouse peritoneal macrophages extracted from Nrf2-KO mice, RAW264.7 treated by the Nrf2 inhibitor trigonelline, or the silencing of Nrf2 by siRNAs in endothelial cells, reversed the anti-inflammatory effect of GW4869, including monocyte adhesion on endothelium, or macrophage inflammation. Moreover, we show that HO-1 expression is increased, suggesting that it may contribute to the anti-inflammatory and antiatherogenic effect observed in response to nSMase inhibition. This is in agreement with reports showing that HO-1 protects against atherosclerosis development, for instance in LDLR −/− mice deficient for HO-1 in bone marrow cells, which develop more atherosclerotic lesions with increased signs of inflammation. Likewise, HO-1-deficient peritoneal macrophages exhibit an increased oxidative burst and inflammatory cytokine production (MCP-1 or IL-6) in response to oxLDLs. 61 However, in our model, it seems that IL-1β and IL-6 production evoked by LPS were early inhibited by GW4869, before any induction of HO-1 expression (Figure 7 ). This suggests that Nrf2 activated in response to GW4869, could also directly block the expression of IL-1β and IL-6, as recently reported by Kobayashi et al. 43 The mechanisms by which ceramide negatively regulates, and conversely, nSMase2 inhibition activates Nrf2, are not yet elucidated. One hypothesis is that ceramide and nSMase2 inhibit the PI3K/Akt pathway, as suggested by Park et al, 41 possibly via an activation of the phosphatase PP2A by ceramide. 62, 63 In contrast, the lack of ceramide could inhibit PP2A, this resulting in a persistent Akt phosphorylation, 28, 64 that could promote Nrf2 stabilization and nuclear translocation. 65, 66 Among the other hypothesis, Nrf2 activation may also result from modifications of the intracellular redox status or of the mitochondrial function in response to nSMase2 inhibition. Further experiments will be necessary to clarify the mechanisms leading to Nrf2 regulation and the place of nSMase2 in this process.
The fact that Nrf2 is implicated in the anti-inflammatory response because of nSMase2 inhibition raises the question of its role in atherosclerosis, which is still debated and controversial. Indeed, if it is generally admitted that the Nrf2 pathway is rather antiatherogenic, via its antioxidant and cytoprotective properties, 67 several reports indicate that Nrf2 may be proatherogenic, by promoting the expression of CD36, 68 or by increasing the plasma and hepatic cholesterol content, 69 or as a positive regulator of the NLRP3 (nucleotide-binding oligomerization domain-like receptors PYD) inflammasome system. 67 As reviewed by Jakobs et al 70 and Mimura and Itoh, 58 the role of Nrf2 could depend on the genetic animal model, the environment, or the stage of atherosclerosis development. In the study reported by Harada et al 71 in ApoE −/− /Nrf2 −/− double KO mice, the lack of Nrf2 was protective against atherosclerosis development, in spite of an increased inflammatory phenotype observed in the early weeks. A proinflammatory role for Nrf2 was also described by Freigang et al, 72 who reported its implication in the activation of the inflammasome NLRP3 by cholesterol crystals, a hallmark of chronic inflammation in advanced atherosclerotic lesions. 73 In contrast, in LDLR −/− mice, Nrf2 deficiency aggravates the development of atherosclerosis in both early and late stages. 74 Likewise, Ruotsalainen et al 75 reported that bone marrow transplantation of Nrf2 −/− to LDLR −/− mice aggravates foam cell formation and inflammation. These discrepancies could be explained by genetic differences between the 2 animal models, as Apoe −/− mice may have a more severe atherogenic phenotype than LDLR −/− mice, which is accelerated and aggravated by high fat and cholesterolenriched diet, 76 prone to activate the NLRP3 inflammasome pathway. 72 In these conditions, (Apoe −/− mice fed with highfat diet), one hypothesis is that the anti-inflammatory and antioxidant properties of the Nrf2/HO-1 pathway could be overwhelmed by the lipid charge, whereas Nrf2 may exert proatherogenic functions such as CD36 overexpression or NLRP3 activation. 72 Our data support a role for Nrf2 in the anti-inflammatory response resulting from the pharmacological or genetic inhibition of nSMase2 in Apoe −/− mice, which is also associated with a reduction of atherosclerotic lesions, implicating or not Nrf2. Indeed, it is likely that nSMase inhibition may generate other antiatherogenic responses, such as a decreased LDL infiltration in the intima, or an inhibition of the exosomal pathway involved in the secretion of proatherogenic miRNAs. 77 More studies will be necessary for understanding the proinflammatory function of nSMase2 in the vessels and its links with atherosclerosis.
In summary, the present study demonstrated that nSMase2 and ceramide play a pivotal role in atherosclerosis in regards to the inflammatory process associated with the development of the lesion. Therefore, targeting nSMase2 may be a new therapeutic strategy to prevent the inflammatory processes involved in atherogenesis.
